Patent details

EN | LT

LT - CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.

EN - CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.

Legal status

Patent not validated

Bibliographic data

Indications of the International Patent Classification (IPC)
(51)	INT.CL.	C07D 405/12
		A61K 31/517

European patent
(11)	Number of the document	1871769
(13)	Kind of document	T
(96)	European patent application number	05818127.2
	Date of filing the European patent application	2005-12-14
(97)	Date of publication of the European application	2008-01-02
(45)	Date of publication and mention of the grant of the patent	2017-02-22
(46)	Date of publication of the claims translation

PCT application
(86)	Number	PCT/GB2005/004807
	Date	2005-12-14

PCT application publication
(87)	Number	WO 2006/064217
	Date	2006-06-22

Priority applications
(30)	Number	Date	Country code
	0427697	2004-12-17	GB

Inventors
(72)	FORD, James Gair AstraZeneca, GB MCCABE, James Francis AstraZeneca, GB O`KEARNEY-MCMULLAN, Anne AstraZeneca, GB O`KEEFE, Philip AstraZeneca R & D Charnwood, GB POINTON, Simon Mark AstraZeneca, GB POWELL, Lyn AstraZeneca, GB PURDIE, Mark AstraZeneca R & D Charnwood, GB WITHNALL, Jane AstraZeneca R & D Charnwood, GB

Grantee
(73)	AstraZeneca AB, 151 85 Södertälje, SE

Title
(54)	CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.
	CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.